Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 5/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24233101 | 0.92 | POLB (0.36) | KMT2APOLBACHETLR9TLR8 | |
| SCHEMBL19312863 | 0.89 | POLB (0.36) | KMT2AOPRM1OPRL1POLBACHE | |
| SCHEMBL26143684 | 0.89 | CHRM5 (0.38) | ACHETLR9TLR8TLR7HRH3 | |
| SCHEMBL23384253 | 0.89 | KMT2A (0.47) | KMT2ACHRM4OPRM1OPRL1ACHE | |
| SCHEMBL22828510 | 0.89 | KMT2A (0.44) | KMT2AACHETLR9TLR8TLR7 | |
| SCHEMBL24294565 | 0.87 | ACHE (0.40) | OPRM1OPRL1ACHETLR9TLR8 | |
| SCHEMBL23384251 | 0.87 | KMT2A (0.43) | KMT2ACHRM4OPRM1OPRL1ACHE | |
| SCHEMBL25122598 | 0.86 | CACNA2D1 (0.39) | KMT2APOLBACHEHRH3KDM4E | |
| SCHEMBL11919254 | 0.85 | KMT2A (0.47) | KMT2ACHRM4OPRM1OPRL1ACHE | |
| SCHEMBL11919044 | 0.85 | KMT2A (0.47) | KMT2AACHEHRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | KMT2A 290/4885CHRM4 4414/4885OPRM1 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.